key: cord-0738601-ipvog4m8 authors: Davoudi-Monfared, E.; Rahmani, H.; Khalili, H.; Hajiabdolbaghi, M.; Salehi, M.; Abbasian, L.; Kazemzadeh, H.; Yekaninejad, M. S. title: Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial date: 2020-05-30 journal: nan DOI: 10.1101/2020.05.28.20116467 sha: bd3bf69e31fccda1bef7d253fc93c6d38941b02d doc_id: 738601 cord_uid: ipvog4m8 Objectives: To the best of our knowledge, there is no published study regarding use of IFN beta-1a in the treatment of severe COVID-19. In this randomized clinical trial efficacy and safety of IFN {beta}-1a has been evaluated in patients with severe COVID-19. Methods: Forty-two patients in the interferon group received IFN beta-1a in addition to the standard of care. Each 44 micrograms/ml (12 million IU/ml) of interferon beta-1a was subcutaneously injected three times weekly for two consecutive weeks. The control group received only the standard of care. Primary outcome of study was time to reach clinical response. Secondary outcomes duration of hospital stay, length of ICU stay, 28-day mortality, effect of early or late administration of IFN on mortality, adverse effects and complications during the hospitalization. Results: As primary outcome, time to the clinical response was not significantly different between the IFN and the control groups (9.7 +/- 5.8 vs. 8.3 +/- 4.9 days respectively, P=0.95). On day 14, 66.7% vs. 43.6% of patients in the IFN group and the control group were discharged, respectively (OR= 2.5; 95% CI: 1.05- 6.37). The 28-day overall mortality was significantly lower in the IFN then the control group (19% vs. 43.6% respectively, p= 0.015). Early administration significantly reduced mortality (OR=13.5; 95% CI: 1.5-118). Conclusion: Although did not change time to reach the clinical response, adding to the standard of care significantly increased discharge rate on day 14 and decreased 28-day mortality. Clinical Trial Registration ID #IRCT20100228003449N28. Severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2) is a novel virus that has been introduced as the first pandemic of the century, since its first detection in late December, 2019 in China [1] . The disease is named as corona virus disease 2019 (COVID-19) and manifests with dyspnea, fever, cough, myalgia and other flu-like symptoms [2] . However, it can progress to more severe disease and causes acute respiratory distress syndrome (ARDS), organ failure and death [3] . In the absence of definite treatment, the disease has caused more than 300,000 deaths worldwide in less than five months [4] . Some antivirals are examining in treatment of COVID-19. However, the results are not sound. Data in term of efficacy of lopinavir-ritonavir were promising at first but recent randomized trial failed to show benefits, especially in later stages of the disease [5] . Hydroxychloroquine is another available choice that has been included in many national recommendations and protocols [6] . However, it has also been advised to restrict this drug for clinical trials due to its questionable efficacy and risk of adverse effects [7] . The race is still on to find an effective . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 30, 2020. . https://doi.org/10.1101/2020.05.28.20116467 doi: medRxiv preprint The antiviral effect of IFNs express through activating interferon-stimulated gene (ISG) that slow viral replication [14] . Additionally, by decreasing the vascular leakage, IFN β -1a improved ARDS complications, regardless of its antiviral properties [15] . Also the higher expression of a protein named CD-73 could lead to better prognosis in ARDS. However, this data was not replicated in larger trial [16] . To the best of our knowledge, there is no published study regarding use of IFN β -1a in the treatment of severe COVID-19. In this randomized clinical trial efficacy and safety of IFN β -1a has been evaluated in patients with severe COVID-19. This open-label randomized clinical trial was conducted to assess efficacy and safety of IFN-β- invasive or invasive respiratory support to provide capillary oxygen saturation above 90%) (2) Hypotension (systolic blood pressure less than 90 mmHg or vasopressor requirement) (3) renal failure secondary to COVID-19 (according to KDIGO definition) [18] (4) neurologic disorder secondary to COVID-19 (decrease of 2 or more scores in Glasgow Coma Scale) (5) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 30, 2020. . https://doi.org/10.1101/2020.05.28.20116467 doi: medRxiv preprint thrombocytopenia secondary to COVID-19 (platelet count less than 150000 /mm3) (6) severe gastrointestinal symptoms secondary to COVID-19 (vomiting/diarrhea that caused at least mild dehydration). Patients with each of the following characteristics were excluded: allergy to IFNs, receiving IFNs for any other reasons, previous suicide attempts, alanine amino transferase (ALT)> 5× the upper limit of the normal range and pregnant women. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 30, 2020. (2) hospital admission, not requiring oxygen (3) hospital admission, requiring oxygen (4) hospital admission, requiring non-invasive positive pressure ventilation (5) hospital admission requiring invasive mechanical ventilation (6) death. Time to clinical response was considered days required to at least two scores improvement in the scale or patient's discharge, which one that occurred sooner. Secondary outcomes were duration of mechanical ventilation, duration of hospital stay, length of ICU stay, 28-day mortality, effect of early or late (before or after 10 days of onset of the symptoms) administration of IFN on mortality, adverse effects and complications during the hospitalization. Following adverse effects of the antiviral regimen/IFN β -1a and complications during the hospitalization course were assessed: gastrointestinal (nausea, vomiting, diarrhea, abdominal pain, pancreatitis), anaphylaxis and allergic reactions (rash, urticaria, angioedema, bronchospasm, and dyspnea related to medication administration), IFN . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 30, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 30, 2020. . https://doi.org/10.1101/2020.05.28.20116467 doi: medRxiv preprint calculated for patients who received IFN early vs. late (after 10 days of starting the symptoms). SPSS software (version 21.0) was used for statistical analyses. During the study period, 139 patients were screened, of whom 103 subjects were eligible. Considering dropped-outs, finally 81 patients (42 in the IFN and 39 in the control group) completed the study (figure 1). Males were 54.3% of patients. The mean ± SD of age in the IFN and control groups was 56.0 ± 16 and 59.5 ± 14 years, respectively. Hypertension (38.3%), cardiovascular diseases (28.4%), diabetes mellitus (27.2%), endocrine disorders (14.8%), and malignancy (11.1%) were common baseline diseases. Endocrine disorders were dyslipidemia and hypothyroidism. There was no significant difference in terms of demographic data and baseline diseases between the groups. The most frequent chief complaints of patients were cough, fever and dyspnea (table 1). APACHE II score at the time of ICU admission was not significantly different between two groups (15.3 ± 4 in the IFN group vs. 14.5 ± 3 in the control group, p= 0.79) Vital signs and laboratory data Median time from starting the symptoms (according to patients' reports) to start IFN was 10 days (IQR: 8-13). The vital signs at the time of hospital admission were not statistically different, except respiratory rate that was significantly higher in the IFN group (24 vs. 22 respectively, p= 0.009). Comparing the baseline laboratory data at the time of hospital admission revealed that mean ± SD of blood urea nitrogen level was higher in the INF than the control group (36 ± 21 vs. 17 ± 8 respectively, p <0.001). Other laboratory findings were comparable (table 2) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 0 Hydroxychloroquine is main medication in Iran's national protocol for the treatment of COVID-19. lopinavir/ritonavir or atazanavir/ ritonavir may be added to hydroxychloroquine in severe cases. The antiviral regimens were not significantly different between two groups. Deep vein thrombosis prophylaxis and stress ulcer prophylaxis were considered for patients if indicated. Based on patients' clinical conditions, azithromycin, intravenous ascorbic acid, antibiotics, intravenous immunoglobulin or a corticosteroid were added to the antiviral regimens. A corticosteroid (methyl prednisolone, hydrocortisone or dexamethasone) was administered for 61.9% and 43.6% of patients in the IFN and the control groups, respectively. Also 35.7% and 25.6% of patients in the IFN and the control group received intravenous immunoglobulin respectively. Supportive care modalities and administered medications are summarized in table 3. As primary outcome, time to the clinical response was not significantly different between the IFN and the control groups (9.7 ± 5.8 vs. 8.3 ± 4.9 days respectively, P=0.95). It has been shown in the Kaplan-Meier plot (figure 2). Also the log rank test revealed that there was no statistically significant difference between the groups, considering time to clinical response (HR= 1.10; 95% CI: 0.64-1.87, p= 0.72). The six-category ordinal scale was assessed at days 0, 7, 14 and 28 (table 4) . On day 0, there was no significant difference between the groups in terms of the components of this scale. On day 7 of therapy, 19% of patients in the INF group were discharged and with no death. At this time, 28% of patients in the control group were discharged and 25% died. However the difference was not statistically considerable (OR= 0.60; 95% CI: 0.21-1.69). On day 14, the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 1 results were statistically notable and 66.7% vs. 43.6% of patients in the IFN group and the control group were discharged, respectively (OR= 2.5; 95% CI: 1.05-6.37). Regarding the time of INF initiation, the analysis showed that early administration significantly reduced mortality (OR=13.5; 95% CI: 1.5-118). However, late administration of INF did not show significant effect (OR=2.1; 95% CI: 0.48-9.6). Other secondary outcomes such as duration of hospital stay, length of ICU stay and duration of mechanical ventilation were not statistically different. However, more patients were extubated in the IFN group (p=0.019). Additionally, the 28-day overall mortality was significantly lower in the IFN then the control group (19% vs. 43.6% respectively, p= 0.015). Complications during the hospitalizations course, incidence of organ failure and adverse effects were not different between the groups. Injection-related side effects (fever, chills, myalgia and headache in few hours after injection of IFN) happened in 8 (19%) patients (table 5) . Hypersensitivity reaction was occurred in one patient who received IFN. The reaction was presented with maculopapular rash on trunk and both upper and lower limbs. Although the patient was taking herbal medicine for cough consisting of thyme and honey, and other medications like hydroxychloroquine and lopinavir-ritonavir concomitantly, interferon was discontinued after fourth dose and rashes begun to disappear within three days. According the Naranjo score the reaction was possibly due to IFN. Neuropsychiatric problems were detected in 4 patients in the IFN group. Two cases experienced severe agitation and two cases complained of mood swing (mostly depression). One of the patients with mood swing had history of mild depressive disorder in past years. Out of 4 cases, two patients were being in the hospital for near to 1 month. Neuropsychiatric side effects of IFN . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 30, 2020. . https://doi.org/10.1101/2020.05.28.20116467 doi: medRxiv preprint are unlikely to happen in short-term use. All patients received psychiatry consult. According the Naranjo score, IFN possibly and probably caused neuropsychiatric problems in three and one patients, respectively. Baseline vital signs and laboratory data were almost comparable between the groups, with some exceptions. The respiratory rate was significantly higher in the IFN group. Also, mean of blood urea nitrogen level was higher in this group. This may be due to higher rate of diarrhea as initial symptoms of COVID-19 in this group in comparison to the control one (19% vs 5.1%). Diarrhea may cause dehydration and lead to higher blood urea nitrogen. As primary outcome of the study, time to reach the clinical response was not significantly different between the groups. In the study of Hung et al, clinical improvement significantly occurred faster in IFN combination therapy group (lopinavir-ritonavir + interferon β -1b + ribavirin) compared with the control group i.e. 7 vs. 12 days [5] . However, it should be noticed that in this study severe cases were excluded. The clinical course of COVID-19 is divided into early viral-replication phase and late cytokinerelease phase [41] . It was suggested that early administration of antiviral medications (within 7-. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Although did not change time to reach the clinical response, adding to the standard of care significantly increased discharge rate on day 14 and decreased 28-day mortality. Improved survival was significant when patients received IFN β -1a in the early phase of the disease. Adverse effects of IFN β -1a were injection-related, neuropsychiatric problems and hypersensitivity reaction that all were tolerable and resolved during the follow-up period. We would like to thank the nurses and other staffs of Imam Khomeini Hospital Complex for their kind supports. The authors did not receive any fund for this work. ReciGen was a generous gift from CinnaGen Co. There is no conflict of interest for authors to declare. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 30, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 30, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 30, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 30, 2020. https://www.ncbi.nlm.nih.gov/books/NBK547918/ . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 30, 2020. . https://doi.org/10.1101/2020.05.28.20116467 doi: medRxiv preprint Deviation . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 30, 2020. . https://doi.org/10.1101/2020.05.28.20116467 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 30, 2020. . https://doi.org/10.1101/2020.05.28.20116467 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 30, 2020. . https://doi.org/10.1101/2020.05.28.20116467 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 30, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 30, 2020. . https://doi.org/10.1101/2020.05.28.20116467 doi: medRxiv preprint 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 30, 2020. ¥ The percentage of extubated patients was calculated according to number of intubated . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 30, 2020. . https://doi.org/10.1101/2020.05.28.20116467 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 30, 2020. . https://doi.org/10.1101/2020.05.28.20116467 doi: medRxiv preprint A novel coronavirus outbreak of global health concern Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease A Trial of Lopinavir-Ritonavir in Adults Hospitalized